BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36476133)

  • 1. Biphenotypic Immunohistochemical Features and NTRK1 Amplification in Intermediate Cell Carcinoma of the Liver.
    Radhakrishnan S; Martin CA; Vij M; Raju LP; Gowripriya G; Jana K; Rammohan A; Jothimani D; Kaliamoorthy I; Veldore VH; Rela M
    Int J Surg Pathol; 2023 Aug; 31(5):839-845. PubMed ID: 36476133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRKA expression and
    Mauri G; Valtorta E; Cerea G; Amatu A; Schirru M; Marrapese G; Fiorillo V; Recchimuzzo P; Cavenago IS; Bonazzina EF; Motta V; Lauricella C; Veronese S; Tosi F; Maiolani M; Rospo G; Truini M; Bonoldi E; Christiansen J; Potts SJ; Siena S; Sartore-Bianchi A
    J Clin Pathol; 2018 Oct; 71(10):926-931. PubMed ID: 29802225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurotrophic tyrosine kinase receptor 1 (TrkA) is overexpressed in oesophageal squamous cell carcinoma.
    Griffin N; Gao F; Jobling P; Oldmeadow C; Wills V; Walker MM; Faulkner S; Hondermarck H
    Pathology; 2021 Jun; 53(4):470-477. PubMed ID: 33143904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features of gastric carcinomas with NTRK-rearrangement/amplification: report of four cases].
    Xu AD; Fu Y; Pu XH; Wu HY; Sun Q; Fan XS
    Zhonghua Bing Li Xue Za Zhi; 2023 May; 52(5):454-459. PubMed ID: 37106286
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma.
    Yu Z; Wang H; Song Q; Huang J; Xu J; Su J; Wang H; Tan L; Wang X; Jiang Z; Chen W; Jiang D; Hou Y
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3113-3121. PubMed ID: 33963905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer.
    Griffin N; Marsland M; Roselli S; Oldmeadow C; Attia J; Walker MM; Hondermarck H; Faulkner S
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32957504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes.
    Terry J; De Luca A; Leung S; Peacock G; Wang Y; Elliot WM; Huntsman D
    Arch Pathol Lab Med; 2011 Apr; 135(4):433-9. PubMed ID: 21466358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
    Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.
    Ge J; Yao B; Huang J; Wu X; Bao H; Ou Q; Shao YW; Chen J
    BMC Cancer; 2019 Jun; 19(1):592. PubMed ID: 31208361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short in-frame deletion in NTRK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensitivity to pain with anhidrosis.
    Sarasola E; Rodríguez JA; Garrote E; Arístegui J; García-Barcina MJ
    BMC Med Genet; 2011 Jun; 12():86. PubMed ID: 21708027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.